76.0JPY
−14.96 BJPY
279.04 BJPY
312.53 M
About SANTEN PHARMACEUTICAL CO
Sector
CEO
Takeshi Ito
Headquarters
Osaka
Website
Employees (FY)
4.14 K
Founded
1890
ISIN
JP3336000009
FIGI
BBG000BJYVK7
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4536 is 1452.5 JPY — it has increased by 0.66% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange SANTEN PHARMACEUTICAL CO stocks are traded under the ticker 4536.
SANTEN PHARMACEUTICAL CO is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
4536 stock is 2.56% volatile and has beta coefficient of 0.33. Check out the list of the most volatile stocks — is SANTEN PHARMACEUTICAL CO there?
One year price forecast for SANTEN PHARMACEUTICAL CO has a max estimate of 2200.0 JPY and a min estimate of 1300.0 JPY.
4536 earnings for the last quarter are 24.13 JPY per share, whereas the estimation was 13.19 JPY resulting in a 82.94% surprise. The estimated earnings for the next quarter are 16.77 JPY per share. See more details about SANTEN PHARMACEUTICAL CO earnings.
SANTEN PHARMACEUTICAL CO revenue for the last quarter amounts to 73.42 B JPY despite the estimated figure of 66.06 B JPY. In the next quarter revenue is expected to reach 73.70 B JPY.
Yes, you can track SANTEN PHARMACEUTICAL CO financials in yearly and quarterly reports right on TradingView.
4536 stock has risen by 0.38% compared to the previous week, the month change is a 0.10% rise, over the last year SANTEN PHARMACEUTICAL CO has showed a 34.74% increase.
4536 net income for the last quarter is 7.33 B JPY, while the quarter before that showed 8.87 B JPY of net income which accounts for −17.36% change. Track more SANTEN PHARMACEUTICAL CO financial stats to get the full picture.
Today SANTEN PHARMACEUTICAL CO has the market capitalization of 506.78 B, it has increased by 2.63% over the last week.
Like other stocks, 4536 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANTEN PHARMACEUTICAL CO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 4.14 K employees. See our rating of the largest employees — is SANTEN PHARMACEUTICAL CO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANTEN PHARMACEUTICAL CO technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANTEN PHARMACEUTICAL CO stock shows the buy signal. See more of SANTEN PHARMACEUTICAL CO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SANTEN PHARMACEUTICAL CO future price: according to them, 4536 price has a max estimate of 2200.00 JPY and a min estimate of 1300.00 JPY. Read a more detailed SANTEN PHARMACEUTICAL CO forecast: see what analysts think of SANTEN PHARMACEUTICAL CO and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANTEN PHARMACEUTICAL CO EBITDA is 71.00 B JPY, and current EBITDA margin is 17.66%. See more stats in SANTEN PHARMACEUTICAL CO financial statements.